NCT02875587View on ClinicalTrials.gov

Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome

PHASE2CompletedINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

December 31, 2018

Conditions

OHSS

Interventions

DRUG

Cabergoline

Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration

DRUG

Calcium gluconate

Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.

Trial Locations (2)

Unknown

Aljazeera hospital, Giza

Riyadh Fertility and Reproductive Health center, Giza

All Listed Sponsors

lead

Aljazeera Hospital

OTHER

NCT02875587 - Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome | Biotech Hunter | Biotech Hunter